DXCM vs STRO · P/E 63, rev $4.03B vs rev $62.0M
DexCom Inc (DXCM) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported DXCM revenue for 2024-12-31 was $4.03B. Net income was $576.2M. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the DXCM and STRO stock pages for the full models.
Not investment advice.